Curated News
By: NewsRamp Editorial Staff
September 02, 2025
Soligenix CEO to Present at H.C. Wainwright Investment Conference Sept 2025
TLDR
- Soligenix CEO's presentation at H.C. Wainwright conference offers investors early insight into potential regulatory approvals and commercialization opportunities for rare disease treatments.
- Soligenix will present at the H.C. Wainwright conference on September 5-10, 2025, with on-demand access and one-on-one meetings available through the platform.
- Soligenix's rare disease treatments and vaccines address unmet medical needs, potentially improving lives worldwide through innovative biopharmaceutical solutions.
- Soligenix develops novel photodynamic therapy for cutaneous T-cell lymphoma and heat-stabilized vaccines using proprietary ThermoVax technology for global health threats.
Impact - Why it Matters
This announcement matters because Soligenix represents a critical player in developing treatments for rare diseases and public health threats that often receive limited attention from larger pharmaceutical companies. Their work on cutaneous T-cell lymphoma, ricin toxin protection, and filovirus vaccines addresses significant unmet medical needs and national security concerns. For investors, the conference presentation offers valuable insight into a company positioned at the intersection of healthcare innovation and government-supported research, potentially representing both financial opportunity and contribution to important medical advancements that could benefit patients worldwide.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases with unmet medical needs, announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The on-demand presentation will be available starting September 5 at 7 a.m. ET through the conference platform, with Soligenix management also participating in one-on-one meetings during the event. This presentation provides investors with crucial insights into the company's progress and future prospects.
The company's Specialized BioTherapeutics segment is advancing HyBryte™ (SGX301) as a novel photodynamic therapy for cutaneous T-cell lymphoma, with successful Phase 3 studies paving the way for potential worldwide commercialization. Additional development programs include synthetic hypericin expansion into psoriasis, dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 for Behçet's Disease. The Public Health Solutions segment features RiVax® ricin toxin vaccine candidate and vaccine programs targeting filoviruses and COVID-19 through CiVax™, all utilizing the proprietary ThermoVax® heat stabilization platform technology supported by government funding from NIAID, DTRA, and BARDA.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix CEO to Present at H.C. Wainwright Investment Conference Sept 2025
